Portal de Periódicos da CAPES

Molecular Detection of Helicobacter pylori and its Antimicrobial Resistance in Brazzaville, Congo

2015; Wiley; Volume: 20; Issue: 4 Linguagem: Inglês

10.1111/hel.12204

1523-5378

Esther Nina Ontsira Ngoyi, Blaise Irénée Atipo Ibara, Rachelle Moyen, Philestine Clausina Ahoui Apendi, J. R. Ibara, O. Obengui, Roland Bienvenu Ossibi Ibara, Etienne Nguimbi, Rock Fabien Niama, J. M. Ouamba, F. Yala, Ange Antoine Abena, Jamuna Vadivelu, Khean‐Lee Goh, Armelle Ménard, Lucie Bénejat, Elodie Sifré, Philippe Lehours, Françis Mégraud,

Gastric Cancer Management and Outcomes

Abstract Back ground Helicobacter pylori infection is involved in several gastroduodenal diseases which can be cured by antimicrobial treatment. The aim of this study was to determine the prevalence of H. pylori infection and its bacterial resistance to clarithromycin, fluoroquinolones, and tetracycline in Brazzaville, Congo, by using molecular methods. Material and Methods A cross‐ sectional study was carried out between September 2013 and April 2014. Biopsy specimens were obtained from patients scheduled for an upper gastrointestinal endoscopy and were sent to the French National Reference Center for Campylobacters and Helicobacters where they were tested by molecular methods for detection of H. pylori and clarithromycin resistance by real‐time PCR using a fluorescence resonance energy transfer‐melting curve analysis ( FRET ‐ MCA ) protocol, for detection of tetracycline resistance by real‐time PCR on 16S rRNA genes ( rrn A and rrn B), for detection of point mutations in the quinolone resistance‐determining regions ( QRDR ) of H. pylori gyr A gene, associated with resistance to quinolones, by PCR and sequencing. Results This study showed a high H. pylori prevalence (89%), low rates of clarithromycin and tetracycline resistance (1.7% and 2.5%, respectively), and a high rate of quinolone resistance (50%). Conclusion Therefore, the use of standard clarithromycin‐based triple therapy is still possible as an empiric first‐line treatment as well as prescription of bismuth‐based quadruple therapy, which includes tetracycline, but not a levofloxacin‐based triple therapy because of the high rate of resistance to fluoroquinolones.